Steven Cohen Longboard Pharmaceuticals, Inc. Transaction History

Point72 Asset Management, L.P.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$17.0 - $27.03 $5.84 Million - $9.29 Million	-343,629 Reduced 24.99%	1,031,371 $27.9 Million
Q1 2024 May 15, 2024	BUY	$18.89 - $26.06 $10.4 Million - $14.3 Million	550,000 Added 66.67%	1,375,000 $29.7 Million
Q2 2023 Aug 14, 2023	SELL	$4.19 - $10.05 $1.78 Million - $4.27 Million	-425,000 Reduced 34.0%	825,000 $6.06 Million
Q1 2023 May 15, 2023	BUY	$3.84 - $5.96 $4.8 Million - $7.45 Million	1,250,000 New	1,250,000 $5.01 Million

126

34.9M

28.9K

13.9K

Ticker LBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 13,586,000
Market Cap $815M
Description
Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing transformative medicines for neurological diseases. The company's lead product candidate is LP352, which is in a Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. Its preclinical ...

Get notified when there are updates to the investment portfolio of Point72 Asset Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Point72 Asset Management, L.P. and Steven Cohen with notifications on news.